Atlas Private Wealth Management increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 18.9% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 25,041 shares of the company’s stock after acquiring an additional 3,987 shares during the period. Johnson & Johnson makes up approximately 2.2% of Atlas Private Wealth Management’s holdings, making the stock its 9th largest holding. Atlas Private Wealth Management’s holdings in Johnson & Johnson were worth $4,145,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Peak Asset Management LLC raised its position in shares of Johnson & Johnson by 9.3% in the 1st quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock valued at $2,137,000 after purchasing an additional 1,171 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Johnson & Johnson by 0.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after purchasing an additional 6,836 shares in the last quarter. Vaughan Nelson Investment Management L.P. raised its position in shares of Johnson & Johnson by 21.8% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock valued at $140,050,000 after purchasing an additional 161,687 shares in the last quarter. Tekla Capital Management LLC raised its position in shares of Johnson & Johnson by 12.8% in the 1st quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock valued at $111,876,000 after purchasing an additional 82,100 shares in the last quarter. Finally, Wisconsin Capital Management LLC raised its position in shares of Johnson & Johnson by 0.8% in the 1st quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock valued at $2,437,000 after purchasing an additional 127 shares in the last quarter. 68.40% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Trading Down 0.7 %
NYSE:JNJ opened at $160.50 on Friday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The stock has a market cap of $417.13 billion, a price-to-earnings ratio of 32.49, a PEG ratio of 3.27 and a beta of 0.54. The business has a fifty day moving average of $166.51 and a 200-day moving average of $162.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were paid a $1.19 dividend. The ex-dividend date was Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s payout ratio is 96.36%.
Insider Activity at Johnson & Johnson
In other news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider William Hait sold 14,698 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on JNJ shares. Atlantic Securities upped their target price on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research report on Friday, August 4th. Credit Suisse Group upped their price target on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. Raymond James dropped their price target on Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 5th. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. Finally, Barclays dropped their price target on Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating on the stock in a research report on Friday, September 8th. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $170.65.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Comparing and Trading High PE Ratio Stocks
- 3 Reasons This Sleeping Giant Is About To Wake Up
- How to Invest in Cannabis, Step by Step
- MarketBeat Week in Review – 9/18 – 9/22
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 52-week Low Names To Tip The Upside Scale In Your Favor
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
